In enteropancreatic NETs, median progression-free survival was not reached with lanreotide versus 18.0 months with placebo (hazard ratio 0.47, 95% CI 0.30-0.73, P<0.001).
In plain wordsIn patients with enteropancreatic NETs, lanreotide prolonged time without disease progression compared with placebo.
- Peptide
- Lanreotide
- Outcome
- IncreaseProgression-free survival
- Study
n = 204
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Tumor growth · Cancer
- Studied dose
- 120 mg every 28 days · 96 weeksAs given in this study (human).
Measurements
- Median progression-free survival
- 18 months
- placebo
- Hazard ratio for progression or death
- 0.47 hazard ratio
- lanreotide vs placebo
- 95% CI of hazard ratio
- 0.3 to 0.73 hazard ratio
- lanreotide vs placebo
- P value
- < 0.001 p-value
- stratified log-rank test
Source sentences
Lanreotide, as compared with placebo, was associated with significantly prolonged progression-free survival (median not reached vs. median of 18.0 months, P<0.001 by the stratified log-rank test; hazard ratio for progression or death, 0.47; 95% confidence interval [CI], 0.30 to 0.73).
2 context sentences(design, population, supporting numbers)
The tumors originated in the pancreas, midgut, or hindgut or were of unknown origin.
Patients were randomly assigned to receive an extended-release aqueous-gel formulation of lanreotide (Autogel [known in the United States as Depot], Ipsen) at a dose of 120 mg (101 patients) or placebo (103 patients) once every 28 days for 96 weeks.